Aggressive natural killer cell leukemia therapy in the L-asparaginase era: why are we failing? [0.03%]
L-天冬酰胺酶时代后难治复发侵袭性自然杀伤细胞白血病为何疗效差？
Sang Eun Yoon,Junhun Cho,Hyun-Young Kim et al.
Sang Eun Yoon et al.
Purpose: Aggressive natural killer cell leukemia (ANKL) is a rare malignancy with poor prognosis and unclear treatment strategies. Given the poor prognosis and lack of a standardized treatment for ANKL, this study aimed t...
Jongheon Jung
Jongheon Jung
The treatment landscape for patients with multiple myeloma (MM) who are ineligible for transplant has evolved significantly over time. Initially dominated by melphalan-based regimens, treatment options have progressed with the introduction ...
Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes [0.03%]
新型药物和低危骨髓增生异常综合征患者贫血管理策略的演变
Junshik Hong
Junshik Hong
Recent developments in the treatment of lower-risk myelodysplastic syndromes have focused on improving anemia management, which remains a major clinical challenge. Erythropoiesis-stimulating agents (ESAs) and lenalidomide are the standard t...
Molecular spectrum and carrier frequency of deletional hereditary persistence of fetal hemoglobin and delta-beta thalassemia in Malaysia [0.03%]
马来西亚胎儿血红蛋白和δ-β地中海贫血基因型的分子光谱及等位基因频率
Faidatul Syazlin Abdul Hamid,Sabariah Md Noor,Mei I Lai et al.
Faidatul Syazlin Abdul Hamid et al.
Purpose: Thalassemia is a major public health concern in Southeast Asia, particularly in Malaysia, where a high carrier rate places significant pressure on healthcare systems. Hereditary Persistence of Fetal Hemoglobin (H...
RUNX1 alterations and survival outcomes in AML: leukocyte dynamics and thrombocytosis insights from an Indonesian cohort [0.03%]
RUNX1改变与急性髓系白血病的生存结局：来自印度尼西亚队列的白细胞动态和血小板增多症洞察
Ikhwan Rinaldi,Elly Yanah Arwanih,Kevin Winston et al.
Ikhwan Rinaldi et al.
Purpose: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with varying prognostic outcomes. This study aimed to observe potential patterns or association between RUNX1 mutations and clinical features...
Progression of carotid plaque burden in patients with polycythemia vera and essential thrombocythemia [0.03%]
血管增多症和必要血小板增多症患者的颈动脉斑块负担进展情况
Seong Soon Kwon,Sun Young Jeong,Min-Young Lee et al.
Seong Soon Kwon et al.
Purpose: Prevention of vascular events is the main objective in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Carotid ultrasonography (USG) is a safe and noninvasive diagnostic tool that can be u...
Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea [0.03%]
韩国T细胞淋巴瘤患者长期结局的真实世界数据全国性研究
Dong Won Baek,Jung Min Lee,Youngeun Jang et al.
Dong Won Baek et al.
Background: Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of aggressive malignancies. This study aimed to comprehensively analyze patients diagnosed with PTCLs in Korea, evaluating treatment outco...
Association of product of platelet and neutrophil count with monoclonal gammopathy of undetermined significance: a cross-sectional analysis of the NHANES [0.03%]
血小板与中性粒细胞计数乘积与未明确定义意义的单克隆丙种球蛋白血症之间的关联：来自NHANES的横断面分析研究
Lijie Wang,Peiyao Yang,Huijie Nan et al.
Lijie Wang et al.
Background: Inflammation indices are emerging predictors of diseases. Monoclonal gammopathy of undetermined significance (MGUS) is a precancerous state and chronic inflammation may drive MGUS progression. This study aimed...
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors [0.03%]
布鲁顿酪氨酸激酶抑制剂治疗血液系统恶性肿瘤患者引起的乙型肝炎病毒再激活
Joon Young Hur,Jung-Hee Lee,Je-Hwan Lee et al.
Joon Young Hur et al.
Purpose: Bruton tyrosine kinase inhibitors (BTKis) are effective and well-tolerated treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Here, we describe the clinical characteristics of hepat...